A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
Information source: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Candidiasis, Oral; Gastrointestinal Diseases; Stomatitis
Intervention: Nystatin (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: National Cancer Institute (NCI)
Summary
In patients who are receiving intravenous high dose Interleukin-2, patients will be
randomized into two groups: group one will receive nystatin swish and swallow immediately
before initiation of IL-2, and the second group will receive a placebo. The patients in
each group will be monitored and evaluated for differences in the rate and severity of
development of oral irritation during treatment. They will also be studied for differences
between the two groups in the number of doses of IL-2 taken.
Clinical Details
Official title: A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
Study design: Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
Detailed description:
In patients who are receiving intravenous high dose Interleukin-2, patients will be
randomized into two groups: group one will receive nystatin swish and swallow immediately
before initiation of IL-2, and the second group will receive a placebo. The patients in
each group will be monitored and evaluated for differences in the rate and severity of
development of oral irritation during treatment. They will also be studied for differences
between the two groups in the number of doses of IL-2 taken.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
All patients enrolled on high dose intravenous interleukin-2 studies in the Surgery Branch
of the National Cancer Institute are eligible, except for patients who are receiving
adoptively transferred cells (cloned peripheral blood cells).
All inclusion criteria as stated in the parent immunotherapy protocol apply:
No patients with evidence of oral irritation prior to starting therapy;
No patients with any known sensitivity to nystatin;
No patients receiving systemic antifungals;
No patients with active oral infections.
In additional, all exclusion criteria as stated in the parent immunotherapy protocol.
Locations and Contacts
National Cancer Institute (NCI), Bethesda, Maryland 20892, United States
Additional Information
Related publications: Marmary Y, Shiloni E, Katz J. Oral changes in interleukin-2 treated patients: a preliminary report. J Oral Pathol Med. 1992 May;21(5):230-1. Rodriguez-Archilla A, Urquia M, Cutando A, Asencio R. Denture stomatitis: quantification of interleukin-2 production by mononuclear blood cells cultured with Candida albicans. J Prosthet Dent. 1996 Apr;75(4):426-31. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485-92.
Starting date: April 1999
Last updated: March 3, 2008
|